The current state of the issue of drug-induced hypoprolactinemia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Hypoprolactinemia is the least studied hormonal deficiency of the anterior pituitary gland. To date, most studies have been devoted to hyperprolactinemia, and there is practically no data on it in the Russian literature.

The purpose of the review is to analyze current literature data on drug–induced hypoprolactinemia and its clinical consequences.

The following keywords and their combinations in Russian and English were used for the search: “hypoprolactinemia”, “drug-induced hypoprolactinemia”, “pituitary gland”, “adenoma”, “prolactinoma”, “dopamine receptor agonists”, “antipsychotic drugs”. As a result of the selection, 82 studies were included in the review.

Human prolactin is a multifunctional hormone that performs many tasks besides stimulating lactation. Unlike hyperprolactinemia, which is characterized by a clear clinical phenotype and the availability of treatment recommendations, the studies of hypoprolactinemia are relatively new. Modern ideas about the ideal level of prolactin in men and women remain incomplete. Drug-induced hypoprolactinemia is usually determined based on the lower limit of the reference values based on the results of tests and can be detected by various specialists, including endocrinologists, therapists, psychologists and psychiatrists. This problem opens up opportunities for interdisciplinary collaboration. Patients with hypoprolactinemia need to be monitored for metabolic, cardiovascular, psychological and sexual disorders.

About the authors

Ilona M. Abieva

North Ossetian State Medical Academy

Author for correspondence.
Email: doccomiss@rambler.ru
ORCID iD: 0009-0006-7588-1780
Russian Federation, Vladikavkaz

Aslan O. Karsanty

North Ossetian State Medical Academy

Email: aslan.karsanty@mail.ru
ORCID iD: 0009-0009-0728-3019
Russian Federation, Vladikavkaz

Diana A. Margieva

North Ossetian State Medical Academy

Email: diana.31263@icloud.com
ORCID iD: 0009-0003-0912-6240
Russian Federation, Vladikavkaz

Irina G. Gabeeva

North Ossetian State Medical Academy

Email: irisha.gabeeva@mail.ru
ORCID iD: 0009-0001-4359-0632
Russian Federation, Vladikavkaz

Zarina S. Kochieva

North Ossetian State Medical Academy

Email: kzsoslanovna@mail.ru
ORCID iD: 0009-0006-1154-7273
Russian Federation, Vladikavkaz

Marina D. Tsibirova

North Ossetian State Medical Academy

Email: marina.tsibirova@mail.ru
ORCID iD: 0009-0001-2191-4747
Russian Federation, Vladikavkaz

Linda F. Saifutdinova

Bashkir State Medical University

Email: linda.sajfutdinova@bk.ru
ORCID iD: 0009-0009-7575-0627
Russian Federation, Ufa

Amanda F. Saifutdinova

Bashkir State Medical University

Email: amanda.sajfutdinova@bk.ru
ORCID iD: 0009-0007-1767-377X
Russian Federation, Ufa

Anna I. Eremenko

Pirogov Russian National Research Medical University

Email: aneremenkoo@gmail.com
ORCID iD: 0009-0009-3478-0985
Russian Federation, Moscow

Margarita V. Shtumm

Burdenko Voronezh State Medical University

Email: Missmargarita99@mail.ru
ORCID iD: 0009-0002-9495-8190
Russian Federation, Voronezh

Violetta A. Bondarchuk

Kuban State Medical University

Email: viva2001@mail.ru
ORCID iD: 0009-0007-0700-832X
Russian Federation, Krasnodar

Nadezhda A. Sobachkina

Burdenko Voronezh State Medical University

Email: nadyusha.sobachkina@gmail.com
ORCID iD: 0009-0007-5544-4142
Russian Federation, Voronezh

Darya D. Fomina

Burdenko Voronezh State Medical University

Email: fomi.darya@gmail.com
ORCID iD: 0009-0004-8916-338X
Russian Federation, Voronezh

Aiguzel A. Khalikova

Bashkir State Medical University

Email: khalikovaayguzel@yandex.ru
ORCID iD: 0009-0007-0796-6376
Russian Federation, Ufa

References

  1. Nad’ YuG, Nad’ RB. Hypoprolactinemia — myth or reality? Eastern European Scientific Journal. 2015;1(1):45–48. (In Russ.) EDN: VATNLP
  2. Dedov II, Melnichenko GA, Dzeranova LK, et al. Clinical guidelines ‘Hyperprolactinemia’ (draft). Obesity and metabolism. 2023;20(2):170–188. (In Russ.) EDN: TIVRBM doi: 10.14341/omet13002
  3. Volkova AR, Ostroukhova EN, Dora SV, et al. Sheehan syndrome in a patient with thyroid pathology. Endokrinologiya: novosti, mneniya, obuchenie. 2020;9(1):77–80. EDN: MDZRZA doi: 10.33029/2304-9529-2020-9-1-77-80
  4. Maseroli E, Verde N, Cipriani S, et al. Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile. J Endocrinol Invest. 2023;46(12):2481–2492. doi: 10.1007/s40618-023-02101-8
  5. Spaggiari G, Costantino F, Granata ARM, et al. Prolactin and spermatogenesis: new lights on the interplay between prolactin and sperm parameters. Endocrine. 2023;81(2):330–339. doi: 10.1007/s12020-023-03375-x
  6. Corona G, Wu FC, Rastrelli G, et al. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med. 2014;11(1):240–253. doi: 10.1111/jsm.12327
  7. Munro V, Wilkinson M, Imran SA. Neuropsychological complications of hypoprolactinemia. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09892-y
  8. Karaca Z, Unluhizarci K, Kelestimur F. Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus: “Absence of proof is not the proof of absence”. Rev Endocr Metab Disord. 2023. doi: 10.1007/s11154-023-09847-9
  9. Dzeranova LK, Aboishava LA, Fedorova NS, et al. Difficulties in diagnosis of adenomas with mixed prolactin and growth hormone secretion: case presentation. Obesity and metabolism. 2020;17(3):233–240. EDN: GWKCST doi: 10.14341/omet12669
  10. Gubernatorov YeYe, Gerasimov GA. Dopaminergic control of prolactin secretion regulation (review of experimental and clinical trials). Problems of Endocrinology. 1994;40(5):55–59. EDN: OVMMJW doi: 10.14341/probl12175
  11. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17(6):639–669. doi: 10.1210/edrv-17-6-639
  12. Akhkubekova NK. Interactions of estrogens, progesterone, and dopamine in regulation of prolactin secretion. Problems of Endocrinology. 2009;55(6):46–48. EDN: KQERRF doi: 10.14341/probl200955646-48
  13. Bernard V, Young J, Binart N. Prolactin — a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019;15(6):356–365. doi: 10.1038/s41574-019-0194-6
  14. Schock H, Zeleniuch-Jacquotte A, Lundin E, et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth. 2016;16(1):146. doi: 10.1186/s12884-016-0937-5
  15. Camilletti MA, Abeledo-Machado A, Faraoni EY, et al. New insights into progesterone actions on prolactin secretion and prolactinoma development. Steroids. 2019;152:108496. doi: 10.1016/j.steroids.2019.108496
  16. Kirsch P, Kunadia J, Shah S, Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: A review. Front Endocrinol (Lausanne). 2022;13:1002320. doi: 10.3389/fendo.2022.1002320
  17. Grattan DR. 60 years of neuroendocrinology: The hypothalamo-prolactin axis. J Endocrinol. 2015;226(2):101–122. doi: 10.1530/JOE-15-0213
  18. Phillipps HR, Yip SH, Grattan DR. Patterns of prolactin secretion. Mol Cell Endocrinol. 2020;502:110679. doi: 10.1016/j.mce.2019.110679
  19. Zaidi M, Yuen T, Kim SM. Pituitary crosstalk with bone, adipose tissue and brain. Nat Rev Endocrinol. 2023;19(12):708–721. doi: 10.1038/s41574-023-00894-5
  20. Dzeranova LK, Vorotnikova SY, Shutova AS, et al. Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment. Obesity and metabolism. 2023;20(3):251–258. EDN: GIAPWT doi: 10.14341/omet13036
  21. Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152(2):526–535. doi: 10.1210/en.2010-0668
  22. Tolgaeva EA, Loktionova AS, Ilovaiskaya IA. The interaction of prolactin and kisspeptin in conditions of normo- and hyperprolactinemia. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(2):35-40. EDN: ZJGNVE doi: 10.17116/rosakush20202002135
  23. Toledano Y, Lubetsky A, Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. J Endocrinol Invest. 2007;30:268–273. doi: 10.1007/BF03346292
  24. Mukherjee A, Ryder WD, Jöstel A, Shalet SM. Prolactin deficiency is independently associated with reduced insulin-like growth factor I status in severely growth hormone-deficient adults. J Clin Endocrinol Metab. 2006;91(7):2520–2525. doi: 10.1210/jc.2005-2491
  25. Mukherjee A, Murray RD, Columb B, et al. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis. Clin Endocrinol (Oxf). 2003;59(6):743–748. doi: 10.1046/j.1365-2265.2003.01916.x
  26. Uzun I, Karaca Z, Hacioğlu A, et al. The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions. Pituitary. 2024;27(3):277–286. doi: 10.1007/s11102-024-01393-0
  27. Kopczak A, Kilimann I, von Rosen F, et al. Screening for hypopituitarism in 509 patients with traumatic brain injury or subarachnoid hemorrhage. J Neurotrauma. 2014;31(1):99–107. doi: 10.1089/neu.2013.3002
  28. Diri H, Tanriverdi F, Karaca Z, et al. Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder. Eur J Endocrinol. 2014;171(3):311–318. doi: 10.1530/EJE-14-0244
  29. Han TS, Antonio L, Bartfai G, et al. Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09890-0
  30. Urhan E, Karaca Z. Diagnosis of hypoprolactinemia. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09896-8
  31. Khan A, Di Dalmazi G, Najafian Zahmatkeshan K, Caturegli P. Isolated hypoprolactinemia: The rarest of the rare? Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09901-0
  32. Toledano Y, Lubetsky A, Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. J Endocrinol Invest. 2007;30(4):268–273. doi: 10.1007/BF03346292
  33. Shutova AS, Pigarova EA, Lepeshkina LI, et al. Overcoming therapy resistance in prolactinomas: from perspectives to real clinical practice. Problems of Endocrinology. 2023;69(6):63–69. EDN: ASHBUK doi: 10.14341/probl13351
  34. Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722–740. doi: 10.1038/s41574-023-00886-5
  35. Harris K, Murphy KE, Horn D, et al. Safety of cabergoline for postpartum lactation inhibition or suppression: a systematic review. J Obstet Gynaecol Can. 2020;42(3):308–315. doi: 10.1016/j.jogc.2019.03.014
  36. Tsiberkin AI, Karonova TL, Dalmatova AB, Grineva EN. The efficacy of dopamine agonist therapy in a young man with a giant prolactinoma: case report. Problems of Endocrinology. 2017;63(4):231–235. EDN: ZKAXDN doi: 10.14341/probl2017634231-235
  37. Melmed S, Casanueva FF, Hoffman AR, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288. doi: 10.1210/jc.2010-1692
  38. Biagetti B, Sarria-Estrada S, Ng-Wong YK, et al. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur J Endocrinol. 2021;185(4):587–595. doi: 10.1530/EJE-21-0561
  39. Akinduro OO, Lu VM, Izzo A, et al. Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure. World Neurosurg. 2019;129:e686–e694. doi: 10.1016/j.wneu.2019.05.249
  40. Giraldi EA, Ioachimescu AG. The role of dopamine agonists in pituitary adenomas. Endocrinol Metab Clin North Am. 2020;49(3):453–474. doi: 10.1016/j.ecl.2020.05.006
  41. Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr J. 2013;60(4):507–515.
  42. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152(4):569–574. doi: 10.1530/eje.1.01888
  43. Mattar P, Alves Martins MR, Abucham J. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology. 2010;92(2):120–127. doi: 10.1159/000317314
  44. Popescu AD, Carsote M, Valea A, et al. Approach of acromegaly during pregnancy. Diagnostics (Basel). 2022;12(11):2669. doi: 10.3390/diagnostics12112669
  45. Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020;21(4):667–678. doi: 10.1007/s11154-020-09588-z
  46. Feelders RA, Fleseriu M, Kadioglu P, et al. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease. Front Endocrinol (Lausanne). 2023;14:1165681. doi: 10.3389/fendo.2023.1165681
  47. Burman P, Edén-Engström B, Ekman B, et al. Limited value of cabergoline in Cushing’s disease: a prospective study of a 6-week treatment in 20 patients. Eur J Endocrinol. 2016;174(1):17–24. doi: 10.1530/EJE-15-0807
  48. Broersen LHA, Jha M, Biermasz NR, et al. Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis. Pituitary. 2018;21(6):631–641. doi: 10.1007/s11102-018-0897-z
  49. Iglesias P, Biagetti B, Araujo-Castro M, et al. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. J Neurooncol. 2022;160(2):351–359. doi: 10.1007/s11060-022-04149-7
  50. Ayalon-Dangur I, Turjeman A, Hirsch D, et al. Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas. Pituitary. 2024;27(1):52–60. doi: 10.1007/s11102-023-01365-w
  51. Wu T, Duan Y, Jiang J, et al. A century of prolactin: Emerging perspectives as a metabolic regulator. Diabetes Metab Res Rev. 2024;40(6):e3836. doi: 10.1002/dmrr.3836
  52. Pirchio R, Graziadio C, Colao A, et al. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022;13:1015520. doi: 10.3389/fendo.2022.1015520
  53. Kirsch P, Kunadia J, Shah S, Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: A review. Front Endocrinol (Lausanne). 2022;13:1002320. doi: 10.3389/fendo.2022.1002320
  54. Auriemma RS, Scairati R, Pirchio R, et al. Cardiometabolic effects of hypoprolactinemia. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09891-z
  55. Inancli SS, Usluogullari A, Ustu Y, et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine. 2013;44(1):193–199. doi: 10.1007/s12020-012-9857-y
  56. Schwetz V, Librizzi R, Trummer C, et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2017;32(1):155–161. doi: 10.1007/s11011-016-9882-2
  57. dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19(4):800–805. doi: 10.1038/oby.2010.150
  58. Byberg S, Futtrup J, Andreassen M, Krogh J. Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr Connect. 2019;8(10):1395–1404. doi: 10.1530/EC-19-0286
  59. Vinik AI, Cincotta AH, Scranton RE, et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18(6):931–943. doi: 10.4158/EP12187.OR
  60. Garber AJ, Blonde L, Bloomgarden ZT, et al. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013;19(1):100–106. doi: 10.4158/EP12325.OR
  61. Macotela Y, Ruiz-Herrera X, Vázquez-Carrillo DI, et al. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne). 2022;13:1001703. doi: 10.3389/fendo.2022.1001703
  62. Ken-Dror G, Fluck D, Lean MEJ, et al. The relationship between low prolactin and type 2 diabetes. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09886-w
  63. Corona G, Rastrelli G, Comeglio P, et al. The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations. Expert Rev Endocrinol Metab. 2022;17(6):533–545. doi: 10.1080/17446651.2022.2144829
  64. Krysiak R, Kowalcze K, Okopień B. Cardiometabolic profile of young women with hypoprolactinemia. Endocrine. 2022;78(1):135–141. doi: 10.1007/s12020-022-03145-1
  65. Krysiak R, Kowalcze K, Okopień B. Cabergoline-induced hypoprolactinemia may attenuate cardiometabolic effects of atorvastatin: a pilot study. Cardiology. 2022;147(5–6):497–506. doi: 10.1159/000527333
  66. Hamidianjahromi A, Tritos NA. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord. 2022;23(5):1089–1099. doi: 10.1007/s11154-022-09753-6
  67. Bancos I, Nannenga MR, Bostwick JM, et al. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):863–868. doi: 10.1111/cen.12375
  68. Almalki MH, Alsuraikh MA, Almalki E, et al. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary. 2024;27(2):197–203. doi: 10.1007/s11102-024-01383-2
  69. Ioachimescu AG, Fleseriu M, Hoffman AR, et al. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019;180(1):31–40. doi: 10.1530/EJE-18-0682
  70. Ufearo CS, Orisakwe OE. Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin. Clin Pharmacol Ther. 1995;58(3):354–359. doi: 10.1016/0009-9236(95)90253-8
  71. Rastrelli G, Corona G, Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord. 2015;16(3):233–248. doi: 10.1007/s11154-015-9322-3
  72. Corona G, Mannucci E, Jannini EA, et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009;6(5):1457–1466. doi: 10.1111/j.1743-6109.2008.01206.x
  73. Krysiak R, Kowalcze K, Okopień B. Sexual function and depressive symptoms in young women with hypoprolactinaemia. Clin Endocrinol (Oxf). 2020;93(4):482–488. doi: 10.1111/cen.14283
  74. Labad J, Montalvo I, González-Rodríguez A, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. Schizophr Res. 2020;222:88–96. doi: 10.1016/j.schres.2020.04.031
  75. Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013;23(4):282–289. doi: 10.1089/cap.2012.0062
  76. Cicala G, Barbieri MA, Santoro V, et al. Safety and tolerability of antipsychotic drugs in pediatric patients: Data from a 1-year naturalistic study. Front Psychiatry. 2020;11:152. doi: 10.3389/fpsyt.2020.00152
  77. Krøigaard SM, Clemmensen L, Tarp S, Pagsberg AK. A meta-analysis of antipsychotic-induced hypo- and hyperprolactinemia in children and adolescents. J Child Adolesc Psychopharmacol. 2022;32(7):374–389. doi: 10.1089/cap.2021.0140
  78. Propst AJ, Jarvis GE, Margolese HC. Aripiprazole-induced hypoprolactinemia in an adult male with first-episode psychosis. Clin Schizophr Relat Psychoses. 2016;9(4):173–176. doi: 10.3371/CSRP.PRJA.022015
  79. Tasaki M, Yasui-Furukori N, Yokoyama S, et al. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacol Rep. 2021;41(3):379–384. doi: 10.1002/npr2.12190
  80. Sogawa R, Shimomura Y, Minami C, et al. Aripiprazole-associated hypoprolactinemia in the clinical setting. J Clin Psychopharmacol. 2016;36(4):385–387. doi: 10.1097/JCP.0000000000000527
  81. Nagai G, Mihara K, Nakamura A, et al. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry Clin Neurosci. 2012t;66(6):518–524. doi: 10.1111/j.1440-1819.2012.02391.x
  82. Jen YW, Hwang TJ, Chan HY, et al. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? BMC Psychiatry. 2020;20(1):552. doi: 10.1186/s12888-020-02957-7

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. PRISMA flow diagram

Download (391KB)
Indexing metadata

Copyright (c) 2024 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».